Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

4.06EUR
7:36pm IST
Change (% chg)

€-0.02 (-0.49%)
Prev Close
€4.08
Open
€4.10
Day's High
€4.13
Day's Low
€4.05
Volume
43,456
Avg. Vol
61,300
52-wk High
€7.14
52-wk Low
€3.82

Summary

Name Age Since Current Position

Michele Garufi

65 1996 Chairman of the Board and Chief Executive Officer, Member of the Management Committee

Sandrine Gestin

50 2015 Finance Director, Member of the Management Committee

Michael Bergamini

70 2015 Executive Vice President, Chief Scientific Officer, Member of the Management Committee

Gavin Spencer

47 2017 Executive Vice President & Chief Business Officer, Member of the Management Committee

Tomas Navratil

2018 Vice President, Head of Development, Member of the Management Committee

Emmanuelle Pierry

Senior Director of Legal Affairs, Member of the Management Committee

Adrienne Graves

64 2014 Non-Executive Independent Director

Lester Kaplan

69 2014 Non-Executive Independent Director

Jean-Francois Labbe

68 2010 Non-Executive Independent Director

Lauren Silvernail

60 2017 Non-Executive Independent Director

Birgit Stattin Norinder

70 2011 Non-Executive Independent Director

Luzi von Bidder

65 2014 Non-Executive Independent Director

Biographies

Name Description

Michele Garufi

Mr. Michele Garufi has been Chairman of the Board and Chief Executive Officer, Member of the Management Committee of Nicox SA since February 15, 1996. He is also Co-Founder of the Company. Mr. Garufi has experience in business development, licensing and international marketing in the European pharmaceutical industry. Before co-founding the Company in 1996, he was Vice President of the International Division and Director of Licensing at Recordati Italy and Managing Director of Recordati’s subsidiary in Spain. He previously served as Director, International Division at Italfarmaco (1988-1992), Assistant to the General Manager at Poli Chimica (1984-1988), Assistant to the President at Medea Research (1983) and Technical Director of one of the Italian subsidiaries of the Lipha Group (1978-1982). In his career, he also served as a Board member for Novuspharma Srl, Novexel SA, Lica SA and he was co-founder and Board member of Scharper SpA. In addition, Mr. Garufi is co-founder of Delife Srl, an Italian Dermatological Company. He graduated with full honors in Pharmaceutical Chemistry from the University of Milan in 1977. He obtained as well the Pharmacist Degree in 1989.

Sandrine Gestin

Mrs. Sandrine Gestin has been Finance Director and Member of the Management Committee at Nicox SA since January 1, 2015. Mrs. Gestin has over 25 years of experience in accounting and finance. She joined Nicox in 1999 and since then she has held several positions, including Accounting Director, Financial Controller and more recently Finance Director. Mrs. Gestin played a key role in building up Nicox’s Finance department, notably by setting up the IFRS (International Financial Reporting Standards) and implementing the financial reporting system. Before joining Nicox, Mrs. Gestin spent 10 years at IBM France where she had a position in the consolidation of overseas subsidiaries. Mrs. Gestin has an MSTCF Diploma (Maitrise des Sciences et Techniques Comptables et Financieres) from the IAE (Institut d’Administration des Entreprises), Nice, France.

Michael Bergamini

Dr. Michael Bergamini has served as Executive Vice President, Chief Scientific Officer and Member of the Management Committee at Nicox SA since 2015. Dr. Bergamini has over 30 years of experience in the eye care industry. He is an experienced biomedical R&D executive and a leader of pre-clinical and clinical functions and project teams. He has played key roles in the discovery, translation, development, registration, and US and International launch of a dozen pharmaceuticals, as well as several medical device products. Dr. Bergamini has served at the University of North Texas Health Science Center as an Adjunct Professor of Pharmacology & Neuroscience since the late 1990’s, as Director, Office of Clinical Trials from 2009 to 2011, and as Executive-in- Residence and Senior Research Analyst from 2011 to 2014. From 1997 to 2009, he held several senior positions with Alcon Research Ltd., the world’s leader in eye care, including Vice President, Pharmaceutical Development and Glaucoma Development. Prior to its acquisition by Alcon, Dr. Bergamini was Chief Executive Officer of the R&D center for Laboratorios Cusí, S.A., the Spanish market leader in ophthalmic therapeutics & surgical adjuncts. He previously was Vice President of R&D at SOLA/Barnes-Hind, Director of Ophthalmic R&D at the Liposome Company, Inc., and Manager of Pharmacology at Allergan Pharmaceuticals, Inc. Dr. Bergamini holds a PhD in Pharmacology (Biomedical Sciences) from the City University of New York. He is the author of 35 peer-reviewed publications, as well as a number of book chapters and more than a dozen patents.

Gavin Spencer

Dr. Gavin Spencer has been Executive Vice President & Chief Business Officer and Member of the Management Committee of NicOx SA since 2017. Before that, he was Vice President – Business Development at the company. Dr. Spencer has been with Nicox since 2005 and has been key in building and managing the partnerships, including closing the 2006 Pfizer deal and the 2010 Bausch+Lomb deal. He was responsible for identifying ophthalmology opportunities including the 2012 deal with RPS and his team has led the design and communication of the new Nicox corporate identity. Dr. Spencer has a Doctorate in Philosophy in Chemistry from the University of Aberdeen, Scotland. He has over 18 years of experience in the industry, including product development, search, evaluation and licensing of new technologies, alliance management, communications and M&A evaluation. Before joining Nicox he fullfilled roles in the search, evaluation and development of new technologies at Novartis Consumer Health in Nyon, Switzerland, where he was responsible for the search, evaluation and development of new technologies and began his career in the development and evaluation of new products at Boots Healthcare International in the UK.

Tomas Navratil

Dr. Tomas Navratil Ph.D. has been Vice President, Head of Development and Member of the Management Committee of Nicox SA since January 2018. Previously he served as Senior Vice President of Development at Envisia Therapeutics. Previously, Dr. Navratil held a number of executive positions, the most recent being Director of Medical and Scientific Affairs at Inspire Pharmaceuticals in the field of discovery and clinical development of drugs. He is the inventor of several patents and is the author of several publications on ocular and pulmonary drug administration and product development. He holds a Bachelor of Science and a PhD in Chemistry from the University of North Carolina at Chapel Hil, where he is currently a member of the Advisory Committee of the Department of Chemistry.

Emmanuelle Pierry

Ms. Emmanuelle Pierry serves as Senior Director of Legal Affairs and Member of the Management Committee of NICOX SA. She joined the company in 2002. Previously she was a lawyer at the Paris Bar Association for 10 years. She holds a Certificate of Aptitude to the Profession of Lawyer, a dess degree from Universite Paris I Pantheon-Sorbonne and a degree from the Institute of Business Law of the Universite Paris II Pantheon-Assas.

Adrienne Graves

Dr. Adrienne L. Graves, Ph.D. has been Non-Executive Independent Director of NICOX SA since October 22, 2014. She has been co-opted Director of the Company since August 8, 2014. She is Member of the Remuneration Committee and Chairman of the Governance Committee of the Company. She is a global industry leader in ophthalmology. From 2002 to 2010, Dr. Graves was President and Chief Executive Officer of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., progressing through various roles, including Director of International Ophthalmology. Dr. Graves serves as Director on several Corporate Boards, including Akorn, Inc., TearLab Corporation and Surface Pharmaceuticals. Dr. Graves received her AB in Psychology with honors from Brown University (Rhode Island, United States), her PhD in Psychobiology from the University of Michigan (Michigan, United States), and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris (France).

Lester Kaplan

Dr. Lester (Les) J. Kaplan, Ph.D. has been Non-Executive Independent Director of Nicox SA since October 22, 2014. He is Member of the Governance Committee of the company. Dr. Kaplan, PhD, was recently the Executive Chairman of Aciex Therapeutics, Inc., a private, United States-based, ophthalmic development pharmaceutical company, acquired by Nicox in October 2014 as well as a director of ACADIA Pharmaceuticals Inc and Neurotech. Previously he was Executive Vice President of Allergan, Inc. Dr. Kaplan joined Allergan in 1983 and, prior to being appointed to Executive Vice President, was Corporate Vice President, and President, Research and Development, and Global BOTOX from June 1998 to November 2003. He was elected to Allergan’s board of directors in 1994. He was also appointed as member of the board of directors of the Clinical Research Institute of the Foundation for Fighting Blindness. Dr. Kaplan received a PhD in organic chemistry from the University of California (Los Angeles, United States) and he holds a degree in Chemistry from University of Illinois.

Jean-Francois Labbe

Mr. Jean-Francois Labbe has served as Non-Executive Independent Director of Nicox SA since June 16, 2010. He is Member of the Company's Remuneration Committee and Chairman of the Audit Committee. He is Chief Executive Officer of SpePharm Holding BV. Prior to founding SpePharm in 2006, Mr. Labbe was an investor in and Chief Executive Officer of OTL Pharma, a Paris-based specialty pharmaceutical and orphan drug company, which achieved €14M sales in 2004, the year he sold the business to Strakan (now ProStrakan). He also served as a board member of Transgene SA until June 2018. Mr. Labbe has worked for over 35 years in the pharmaceutical industry and was previously Chief Executive Officer of Parke Davis France. Prior to joining Parke Davis, Mr. Labbe worked for Hoechst-Roussel for 25 years where he held various general management positions in Europe (The Netherlands, France, UK) and abroad (USA, South Africa). He became President Europe-Middle East-Africa of Hoechst-Marion-Roussel from 1995 to 1999, serving as a member of the Executive Committee of the group until its merger into Aventis. He was Director of Drug Abuse Sciences from 2005 until 2009, Director of Cavadis B.V. from 2009 to 2010 and Director of Libragen SA from 2001 until 201. Mr. Labbe has an MBA from the HEC Business School, Paris.

Lauren Silvernail

Mrs. Lauren P. Silvernail has been Non-Executive Independent Director of Nicox SA since May 16, 2017. She is Member of company's Audit Committee. Currently she serves also as Chief Business and Financial Officer at Revance Therapeutics. Before joining Revance she served as Vice President of Finance, Administration and Corporate Development of ISTA Pharmaceuticals. Mrs. Silvernail holds MBA from University of California and Bachelor's degree in Biophysics in Berkeley.

Birgit Stattin Norinder

Mrs. Birgit Stattin Norinder has served as Non-Executive Independent Director at Nicox SA as of June 15, 2011. She is also Chairman of the Company's Remuneration Committee and Member of the Governance Committee. Mrs. Stattin Norinder has held several senior Research and Development positions in European and US based Pharmaceutical Companies including Pharmacia & Upjohn (UK) as a member of Corporate Management and Senior Vice-President Worldwide Product Development, Glaxo Group Research Ltd (UK) as Director of International Regulatory Affairs, Astra Research Centre AB (Sweden) as Vice-President of Infection R&D, Pfizer Inc (USA) and Parke-Davis AB (Sweden). Mrs. Stattin Norinder was appointed as Chief Executive Officer and Chairwoman of Prolifix Ltd (UK). She also held several Board and Chairman positions of UK, Swedish and Norwegian biotechnology companies. She was Director of Biolipox AB (2004-2007), Artimplant AB (2004-2007), deCODE Genetics Inc. (2006-2009). Moberg Derma AB (2008-2009), Antisoma Ltd (2003-2011), Wingfirm Pharma AB (2010-2012), Karo Bio AB (2007-2011) and PULS AB (2008-2011). Currently, she is a Board Member of Hansa Medical AB and AddLife in Sweden. Mrs. Stattin Norinder has a Master in Pharmaceutical Sciences from Uppsala University.

Luzi von Bidder

Mr. Luzi Andreas von Bidder has been Non-Executive Independent Director of Nicox SA since October 22, 2014. He has been co-opted Director of the Company since August 11, 2014. He is Member of the Audit Committee of the Company. Mr. Luzi A. von Bidder was until 2014 the Chairman of Acino Holding AG, a pharmaceutical company focused on novel drug delivery forms which was acquired by Pharma Strategy Partners GmbH in December 2013. Mr. von Bidder is currently on the Board of several other private healthcare companies, including Ixodes and Ferring Pharmaceuticals and he is Chairman of Solvias and EyeSense GmbH. Between 1992 and 2002, prior to joining Acino, Mr. von Bidder served as Chairman and Chief Executive Officer of Novartis Ophthalmics AG, a subsidiary of the Swiss arm of Novartis. He also served as a member of the Novartis Pharma Executive Committee and held various positions at Ciba-Geigy. Mr. von Bidder graduated in Economics from HSG University of St. Gallen (Switzerland).